DoD (MTEC) – Oral immunotherapy to prevent endemic diarrheal disease

December 23, 2021 by


On December 21, 2021, the Medical Technology Enterprise Consortium (MTEC) published the Request for Project Proposals (RPP) MTEC-22-03-Diarrheal on the MTEC website and a notice will be posted on to notify interested parties. This RPP is focused on the development of a self-administered oral immunotherapy (not a vaccine) to prevent endemic diarrheal disease by targeting multiple bacterial pathogens. The self-administered oral immunotherapy should mitigate symptoms, shorten the duration of illness, and/or reduce the risk of contracting bacterial diarrheal illnesses. The proposed immunotherapy product would target enterotoxigenic Escherichia coli (ETEC), and at least one other common bacterial diarrheal pathogen such as Campylobacter or Shigella. The oral immunotherapy must be stable without requiring a cold-chain and therefore could be utilized by the Warfighter in austere environments.

Key Dates:

Enhanced White Papers are due no later than February 7, 2022 at 12:00pm Eastern Time. MTEC membership is required for the submission of Enhanced White Papers in response to this MTEC RPP. An Offeror submitting an Enhanced White Paper as the prime contractor must be an MTEC member of good standing at least 3 days prior to submission. To join MTEC, please visit

MTEC Members will be notified when the Proposers Conference is scheduled.

Points of Contact:

Please direct your inquiries and correspondence to the following contacts:

  • Questions concerning contractual, cost or pricing related to this RPP should be directed to the MTEC Contracts Administrator at
  • Technical and membership questions – Dr. Gage Greening, Ph.D., MTEC Biomedical Research Associate,
  • Administrative questions – Ms. Kathy Zolman, MTEC Director of Program Operations,

URL for more information:

To view this solicitation, click here.


Filed Under: Funding Opportunities